AQUESTIVE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.085 USD | -8.73% |
|
-8.32% | +52.72% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 50.11M | Sales 2025 * | 59.2M | Capitalization | 281M |
|---|---|---|---|---|---|
| Net income 2024 * | -27M | Net income 2025 * | -27M | EV / Sales 2024 * | 4.88 x |
| Net cash position 2024 * | 36.32M | Net Debt 2025 * | 15.47M | EV / Sales 2025 * | 5.01 x |
| P/E ratio 2024 * |
-8.62
x | P/E ratio 2025 * |
-10.5
x | Employees | 135 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aquestive Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -8.73% | ||
| 1 week | -8.32% | ||
| Current month | -8.18% | ||
| 1 month | -24.20% | ||
| 3 months | +15.11% | ||
| 6 months | +84.73% | ||
| Current year | +52.72% |
1 week
2.91
3.60
1 month
2.914.54
Current year
1.956.23
1 year
1.256.23
3 years
0.626.40
5 years
0.6210.00
10 years
0.6220.70
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Barber
CEO | Chief Executive Officer | 48 | 07-06-30 |
A. Toth
DFI | Director of Finance/CFO | 65 | 20-12-30 |
Stephen Wargacki
CTO | Chief Tech/Sci/R&D Officer | 46 | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 22-08-09 |
Santo Costa
CHM | Chairman | 78 | 15-11-30 |
Gregory Brown
BRD | Director/Board Member | 70 | 07-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 3.085 | -8.73% | 2,725,338 |
| 24-05-07 | 3.38 | -3.43% | 1,575,339 |
| 24-05-06 | 3.5 | -0.57% | 1,067,531 |
| 24-05-03 | 3.52 | +7.32% | 1,705,602 |
| 24-05-02 | 3.28 | -2.53% | 1,679,513 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Companyâs Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.085
USD
Average target price
9
USD
Spread / Average Target
+191.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.72% | 308M | |
| +32.95% | 700B | |
| +26.51% | 569B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B |
- Stock Market
- Equities
- AQST Stock